PL1830881T3 - Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie - Google Patents

Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie

Info

Publication number
PL1830881T3
PL1830881T3 PL05856275T PL05856275T PL1830881T3 PL 1830881 T3 PL1830881 T3 PL 1830881T3 PL 05856275 T PL05856275 T PL 05856275T PL 05856275 T PL05856275 T PL 05856275T PL 1830881 T3 PL1830881 T3 PL 1830881T3
Authority
PL
Poland
Prior art keywords
receptors
targeting multiple
therapies targeting
toll
multiple toll
Prior art date
Application number
PL05856275T
Other languages
English (en)
Inventor
Greg Elson
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of PL1830881T3 publication Critical patent/PL1830881T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL05856275T 2004-12-10 2005-12-12 Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie PL1830881T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63542104P 2004-12-10 2004-12-10
EP05856275A EP1830881B1 (en) 2004-12-10 2005-12-12 Combining therapies targeting multiple toll-like receptors and use thereof
PCT/IB2005/004174 WO2006077471A2 (en) 2004-12-10 2005-12-12 Combining therapies targeting multiple toll-like receptors and use thereof

Publications (1)

Publication Number Publication Date
PL1830881T3 true PL1830881T3 (pl) 2010-11-30

Family

ID=36692602

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05856275T PL1830881T3 (pl) 2004-12-10 2005-12-12 Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie

Country Status (12)

Country Link
US (1) US8029794B2 (pl)
EP (1) EP1830881B1 (pl)
JP (2) JP5118491B2 (pl)
AT (1) ATE469658T1 (pl)
AU (1) AU2005325482B2 (pl)
CA (1) CA2593561C (pl)
DE (1) DE602005021694D1 (pl)
DK (1) DK1830881T3 (pl)
ES (1) ES2348792T3 (pl)
PL (1) PL1830881T3 (pl)
PT (1) PT1830881E (pl)
WO (1) WO2006077471A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510853T1 (de) * 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
AU2006236588A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US20100143336A1 (en) * 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
PT2173381E (pt) 2007-05-14 2013-12-13 Novimmune Sa Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas
WO2009000929A2 (en) * 2007-06-28 2008-12-31 Opsona Therapeutics Limited Composition and method for treatment of autoimmune disease
AU2008270218B2 (en) 2007-07-05 2012-09-20 Neuramedy Co., Ltd. Compounds and methods for the treatment of renal disease
WO2009019260A2 (en) * 2007-08-03 2009-02-12 Opsona Therapeutics Limited Composition and method for treatment of reperfusion injury and tissue damage
EP2214692A2 (en) * 2007-10-31 2010-08-11 Centocor Ortho Biotech Inc. Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
US8901282B2 (en) 2008-06-13 2014-12-02 Rappaport Family Institute For Research In The Medical Sciences Reagents and methods for detecting a polymorphic protein
EP2356140A2 (en) 2008-10-07 2011-08-17 Novimmune Sa Il-17-mediated transfection methods
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137843A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
PL2831117T3 (pl) * 2012-03-29 2018-03-30 Novimmune Sa Przeciwciała anty-TLR4 i ich zastosowania
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
EP2722342A1 (en) * 2012-10-19 2014-04-23 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
JP6450594B2 (ja) * 2012-12-28 2019-01-09 持田製薬株式会社 プレセプシン測定による炎症性腸疾患の診断
AU2014338991B2 (en) 2013-10-22 2020-06-11 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
US10253105B2 (en) 2014-02-28 2019-04-09 Astellas Pharma Inc. Bispecific antibody binding to human TLR2 and human TLR4
US9730983B2 (en) * 2015-10-02 2017-08-15 Chih-Yuan MA Methods for treatment of CD14-mediated disorders and responses
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US20190315878A1 (en) * 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
EP3554344A1 (en) * 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2019176901A1 (ja) * 2018-03-12 2019-09-19 学校法人日本医科大学 ｍｉｃｒｏＲＮＡ－２１を標的とした変形性関節症による疼痛の緩和
WO2021243396A1 (en) * 2020-06-01 2021-12-09 Implicit Bioscience Limited Therapeutic methods of using cd 14 antagonistic antibodies in treating conditions associated with a coronavirus infection including sars-cov-2 (covid-19)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510909A (ja) 1993-05-28 1996-11-19 ザ スクリップス リサーチ インスティチュート Ｃｄ１４媒介細胞活性化を抑制するための方法および組成物
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US7264967B2 (en) * 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
EP2338497A1 (en) 2001-08-10 2011-06-29 Eisai R&D Management Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
BR0212366A (pt) * 2001-09-07 2004-07-27 Univ Boston Método e composição para tratar distúrbios associados com o complexo imune
ATE510853T1 (de) 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
JPWO2005047330A1 (ja) 2003-11-17 2008-01-24 独立行政法人科学技術振興機構 Ｔｌｒ４−ｍｄ−２複合体を標的としたエンドトキシンショック治療剤
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
PT1711531E (pt) * 2003-12-10 2012-04-18 Novimmune Sa Anticorpos neutralizantes anti tlr4/md-2 e métodos para a sua utilização

Also Published As

Publication number Publication date
DK1830881T3 (da) 2010-09-20
JP2012197316A (ja) 2012-10-18
CA2593561A1 (en) 2006-07-27
PT1830881E (pt) 2010-08-30
AU2005325482A1 (en) 2006-07-27
AU2005325482B2 (en) 2011-06-16
US8029794B2 (en) 2011-10-04
ES2348792T3 (es) 2010-12-14
ATE469658T1 (de) 2010-06-15
WO2006077471A2 (en) 2006-07-27
WO2006077471A3 (en) 2007-04-19
CA2593561C (en) 2017-01-03
DE602005021694D1 (de) 2010-07-15
JP5118491B2 (ja) 2013-01-16
EP1830881A2 (en) 2007-09-12
EP1830881B1 (en) 2010-06-02
US20060165686A1 (en) 2006-07-27
JP2008523048A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
IL184617A0 (en) Dr5 antibodies and uses thereof
IL214325A (en) Antibody against cmet, a drug that includes and uses it
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TW200603828A (en) Treatment of disorders
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MY165273A (en) Anti-cd48 antibodies and uses thereof
MX338397B (es) Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
JO2795B1 (en) Immunoglobulins
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2007038407A3 (en) Compositions and methods for treating nervous system disorders
UA100984C2 (ru) Антитела против nrr notch1 и способы их применения